NASDAQ:SCLXW Scilex (SCLXW) Stock Price, News & Analysis $0.52 +0.04 (+8.35%) As of 03:34 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About Scilex Stock (NASDAQ:SCLXW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Scilex alerts:Sign Up Key Stats Today's Range$0.51▼$0.5750-Day Range$0.09▼$0.5952-Week Range$0.04▼$0.65Volume11,394 shsAverage Volume10,927 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Scilex Holding Company (NASDAQ: SCLXW) is a commercial-stage specialty pharmaceutical company focused on the development, acquisition and commercialization of non-opioid pain management therapies. Its lead product, ZTlido™ (lidocaine topical system 1.8%), is approved in the United States for the relief of neuropathic pain associated with post-herpetic neuralgia. Scilex’s core strategy is to address the growing need for non-addictive alternatives to traditional opioid analgesics by leveraging innovative topical and transdermal delivery technologies. Beyond its marketed portfolio, Scilex maintains a pipeline of clinical and preclinical candidates targeting a range of acute and chronic pain indications. The company applies expertise in formulation science to optimize localized drug delivery, aiming to reduce systemic exposure and minimize side effects. Scilex also pursues strategic partnerships and licensing agreements to expand its product offerings and accelerate development timelines. Headquartered in Fort Worth, Texas, Scilex operates primarily across the United States, supported by a dedicated commercial organization that collaborates with healthcare professionals to enhance patient access and education. The company’s leadership team combines deep experience in specialty pharmaceuticals, commercial execution and regulatory affairs, positioning Scilex to capitalize on unmet needs in the pain management market.AI Generated. May Contain Errors. Read More Receive SCLXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter. Email Address SCLXW Stock News HeadlinesScilex CEO Jaisim Shah to resign, Henry Ji to succeedAugust 22 at 8:15 AM | msn.comScilex Holding Appoints New CEO Amid Leadership ChangeAugust 21 at 7:30 AM | tipranks.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 22 at 2:00 AM | InvestorPlace (Ad)Scilex CEO to resign as focus turns to Semnur – Denali mergerAugust 21 at 7:14 AM | seekingalpha.comScilex (NASDAQ:SCLXW) Stock Price Up 11.5% - Should You Buy?August 14, 2025 | americanbankingnews.comScilex stock jumps after SEC declares S-4 effective for Semnur mergerAugust 13, 2025 | au.investing.comScilex says registration statement on Form S-4 declared effective by SECAugust 13, 2025 | msn.comScilex Shares Rise After SEC Clears S-4 for Semnur MergerAugust 13, 2025 | msn.comSee More Headlines SCLXW Stock Analysis - Frequently Asked Questions How have SCLXW shares performed this year? Scilex's stock was trading at $0.21 at the beginning of 2025. Since then, SCLXW stock has increased by 147.7% and is now trading at $0.5201. How do I buy shares of Scilex? Shares of SCLXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolNASDAQ:SCLXW CIK1820190 Webwww.scilexholding.com Phone650 516 4310FaxN/AEmployees105Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$44.24 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:SCLXW) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.